Target	Probe	Control	Targeted domain	Mode of action	Recommended concentration	Target origin
BCL2L1	A-1155463	A-1107969	BCL domain	Inhibitor	≤ 5 µM	human
BCL2	A-1211212	A-1210227	—	Inhibitor	≤ 5 µM	human
NR3C1	BI 653048	BI-3047	Ligand binding domain	Agonist	1 µM	human
ITGAL	BI-1950	BI-9446	I-domain	Inhibitor	100 nM	human
BCL6	BI-3802	BI-5273	BTB/POZ, binds at interface of 2 monomers	Degrader	≤ 1 µM	human
BCL6	BI-3812	BI-5273	BTB/POZ, binds at interface of 2 monomers	Inhibitor	≤ 1 µM	human
BCL6	CCT369260	CCT393732	BTB domain	Degrader	≤ 1 µM	human
MCL1	JNJ-4355	JNJ-78732576	BCL domain	Inhibitor	≤ 10 µM	human
NRLP3	JNJ-79883960	JNJ-78832000	NACHT domain	Inhibitor	≤ 10 µM	human
RORC	JNJ-54119936	JNJ-53721590	Orthosteric site of binding domain	Inverse agonist	≤ 1 µM	human
RXRA, RXRB, RXRG	JP3000	JP3001	Ligand binding domain	Agonist	0.1 - 1 µM	human
SLC16A3	MSC-4381	MSC-0516	—	Inhibitor	≤ 10 µM	human
BCL6	TP-021	TP-021n	Bric-a-brac (BTB) domain	Inhibitor	1 -10 µM	human